Pharmaceuticals 2010, 3(7), 2213-2224; doi:10.3390/ph3072213
Review

High-Dose Ibuprofen in Cystic Fibrosis

Larry C. Lands 1, 2,* email and Nurlan Dauletbaev 2 email
1 Division of Respiratory Medicine, Montreal Children’s Hospital, D-380, 2300 Tupper Street, Montreal, Quebec, H3H 1P3, Canada 2 Research Institute of McGill University Health Centre, Montreal Children’s Hospital, C-1223, 2300 Tupper Street, Montreal, Quebec, H3H 1P3, Canada
* Author to whom correspondence should be addressed.
Received: 23 June 2010; in revised form: 6 July 2010 / Accepted: 8 July 2010 / Published: 13 July 2010
(This article belongs to the Special Issue Non-Steroidal Anti-Inflammatory Drugs)
PDF Full-text Download PDF Full-Text [123 KB, uploaded 13 July 2010 13:48 CEST]
Abstract: Cystic Fibrosis (CF) is the most common lethal genetic disorder in North America and Europe. Most patients succumb to progressive lung disease characterized by an exaggerated neutrophilic inflammation. In animal models of chronic infection, high-dose ibuprofen was demonstrated to reduce inflammation without hindering bacterial clearance. This led to two clinical trials, which demonstrated a benefit in slowing the progression of lung disease in CF. However, concerns about potential adverse effects have limited the use of high-dose ibuprofen in CF patients. There are a variety of potential mechanisms to account for the observed clinical benefit. A better understanding of these mechanisms could potentially lead to more targeted and better-tolerated anti-inflammatory therapies.
Keywords: ibuprofen; interleukin-8; neutrophils; cystic fibrosis; CFTR

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Lands, L.C.; Dauletbaev, N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals 2010, 3, 2213-2224.

AMA Style

Lands LC, Dauletbaev N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals. 2010; 3(7):2213-2224.

Chicago/Turabian Style

Lands, Larry C.; Dauletbaev, Nurlan. 2010. "High-Dose Ibuprofen in Cystic Fibrosis." Pharmaceuticals 3, no. 7: 2213-2224.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert